The U.S. government has created a high-stakes choice for biotech companies: lower your drug prices or face massive new tariffs.
On April 2, 2026, the White House announced tariffs of up to 100% on imported patented drugs, using a national security law called Section 232. However, this isn't a blanket tax. The policy offers a clear escape route: companies that agree to 'Most-Favored Nation' (MFN) pricing and commit to manufacturing in the U.S. ('onshoring') will be exempt, paying a 0% tariff.
This policy didn't come out of nowhere; it's the result of a long chain of events. First, its foundation was laid in April 2025 when the Commerce Department began a Section 232 investigation into pharmaceuticals. This move was crucial as it framed drug imports as a national security issue, providing the legal basis for the tariffs.
Second, throughout late 2025 and early 2026, large pharmaceutical giants like Pfizer and Johnson & Johnson had already signed "voluntary" agreements. They agreed to lower prices and invest in U.S. facilities in exchange for tariff relief, establishing a clear template for the current policy.
Third, a key trigger was a February 2026 Supreme Court decision that limited the administration's power to impose tariffs under a different law. This forced a pivot to the more robust Section 232, making the tariff threat much more credible and immediate.
The policy is designed to put maximum pressure on smaller and mid-size biotech firms. Unlike large pharma, these companies often have fewer products, less capital, and rely heavily on overseas manufacturing. For them, the choice between accepting lower prices through MFN deals or absorbing a 100% tariff is a difficult, and in some cases existential, decision. The market's initial reaction was muted, as investors noted exemptions for orphan drugs and cell therapies, but the pressure on individual companies remains intense.
- Section 232: A U.S. trade law that allows the president to impose tariffs on imports if they are found to threaten national security.
- Most-Favored Nation (MFN) Pricing: A policy that would require drug manufacturers to sell their drugs in the U.S. at a price no higher than the lowest price they charge in other developed countries.
- Onshoring: The process of moving business operations, such as manufacturing, from overseas back to the company's home country.